After weeks of buildup and controversial delays, Moderna has launched its pivotal study to determine whether their Covid-19 vaccine actually works. And BARDA is committing another $472 million to get them there.

The 30,000 person study will test whether two 100 g doses of their mRNA vaccine can prevent people from becoming symptomatic with Covid-19. The launch marks the beginning of a second stage in the hunt for a coronavirus vaccine, as the most well-backed and advanced efforts having been tested for safety and immunogenicity in small groups of volunteers move into studies that will determine whether they can actually prevent Covid-19 and be available in the fall or winter to stem the pandemic.

Unlock this story instantly and join 85,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

More here:

GV's David Schenkein comes in to help mentor and bankroll a gene therapy 2.0 player, intrigued by their 'science heavy' approach to conquering...